Headquartered in Summit, NJ Fiscal year ends December NYSE: KVUE kenvue.com
Kenvue Inc. is the world's largest pure-play consumer health company by revenue, operating across three business segments: Self Care (pain relief, cough/cold, allergy, digestive health, smoking cessation), Skin Health and Beauty (face care, hair care, sun care), and Essential Health (oral care, baby care, wound care, women's health). The company's portfolio includes iconic, science-backed brands such as Tylenol, Zyrtec, Pepcid, Nicorette, Neutrogena, Aveeno, OGX, Listerine, Band-Aid, Johnson's, Stayfree, and Codral, many recommended by healthcare professionals worldwide. Kenvue sells its products globally across North America, EMEA, Asia Pacific, and Latin America through retail, pharmacy, and eCommerce channels. Originally separated from Johnson & Johnson, the company is currently subject to a pending acquisition by Kimberly-Clark under a definitive merger agreement announced in November 2025, with closing expected in Q4 2026. Updated
Kimberly-Clark has raised its dividend for over five decades, but a looming $48 billion acquisition and razor-thin cash flow coverage are putting that streak under pressure most income investors haven't noticed yet.
While nervous investors obsess over a handful of tech giants propping up the whole market, one portfolio manager keeps funneling fresh cash into the brands sitting in every American medicine cabinet, and…
One of these stocks lost nearly a fifth of its value over the past year, another nearly doubled, and both still handed shareholders a bigger check. Find out whether the dividends behind…
Kimberly-Clark just logged its 54th straight year of dividend increases, but a shrinking raise, falling free cash flow, and a massive acquisition in progress raise a pointed question for income investors living…
Rising rates have boomers flocking to Treasuries, but five battle-tested dividend payers with 50-plus years of consecutive increases may offer something bonds simply cannot deliver.
Kimberly-Clark (NASDAQ:KMB | KMB Price Prediction) pays a quarterly dividend of $1.28 per share. That is an annualized forward rate of $5.12 and a yield of 5.16%. The problem sits right next…
While investors pile into pricey AI darlings, a handful of battle-tested Dividend Kings have quietly slipped to levels that scream value, and Wall Street analysts see serious upside ahead for 2027.
Younger investors are rewriting the rules of wealth building, and five overlooked dividend stocks under $20 sit right at the center of that shift. The real question is whether these picks can…
Colgate is reportedly shopping Softsoap, Irish Spring, and Speed Stick with Goldman Sachs running the process, but the names most investors would expect to step up all have reasons to sit this…
Kimberly-Clark just raised its dividend for the 54th straight year while simultaneously chasing a nearly $50 billion acquisition, and income investors are now weighing whether a deal of that size can coexist…
Kenvue just snapped a four-quarter earnings streak while Reddit falls nearly silent, and the reason why tells you everything about where this stock goes next.
Black Monday wiped out 22% of the market in a single day, and most investors never saw it coming. A small group of companies not only survived that crash and every major…
While growth investors scrambled for cover in 2026, a quiet group of battle-tested income stocks started leaving the S&P 500 in the dust. Four Dividend Kings with decades of unbroken payouts are…
Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash,…
Passive income is characterized by its ability to generate revenue without requiring the earner’s continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or…
Kenvue Inc. is the world's largest pure-play consumer health company by revenue, operating across three business segments: Self Care (pain relief, cough/cold, allergy, digestive health, smoking cessation), Skin Health and Beauty (face care, hair care, sun care), and Essential Health (oral care, baby care, wound care…
24/7 Wall St.'s 12-month price target for KVUE is $20.61, rated Buy. The Wall Street consensus target is $19.50. KVUE price prediction →
